{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"MTD was determined by testing dose-de-escalation to 20mg PO daily on dose de-escalation cohort 1 to 2 with 3 to 6 patients each. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in \\> 33% of participants. Toxicities will be graded according to the CTEP Active Version of the NCI Common Terminology Criteria for Adverse Events. Dose-limiting toxicities (DLT) apply only during Cycle 1 and must be drug-related (i.e. possibly, probably or definitely related to one of the 3 study drugs). The following events occurring in the first cycle of treatment are considered dose limiting.\n\n1. Febrile neutropenia\n2. Grade 4 neutrophil count decrease for more than 7 days' duration\n3. Grade 4 platelet count decrease\n4. Grade 3 or 4 non-hematologic toxicity (excluding alopecia)","groups":[{"description":"All participants from Phase I who are eligible for DLT. Patients will be considered evaluable for DLT if they received at least 14 doses of cediranib at the assigned dose during Cycle 1 and at least one dose each of pemetrexed and cisplatin, or if they developed a DLT. If a patient does not develop a DLT but does not complete at least 14 doses of cediranib and one dose each of pemetrexed and cisplatin during Cycle 1 due to any reason, the patient will be considered not evaluable for DLT and will be replaced.","id":"OG000","title":"All Phase I Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Weekly during first cycle (1cycle = 21 days). Then will be reported every cycle while patient is on treatment.","title":"Maximum Tolerated Dose of Cediranib in Combination With Cisplatin and Pemetrexed (Phase I)","type":"PRIMARY","unitOfMeasure":"mg"}